Trial Profile
An Open Label Randomized Phase II Study of Oral Treatment With BIBF 1120 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 15 Jul 2014 New trial record